

To,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400001.

Date: 14.11.2019

Dear Sir/Madam,

Sub: Outcome of board meeting under regulation 30 read with 33 (3). (c) of SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015

Ref: Sangam Health Care Products Limited (Scrip code: 531625)

With reference to the subject cited, this is to inform the Exchange that at the Board meeting of M/s Sangam Health Care Products Limited held on Thursday, the 14th day of November, 2019 at 04:00 P.M. at the registered office of the company were duly considered and approved by the Board:

1. Un-audited Financial Results of the company as per IndAS for the quarter ended September 30, 2019 and
2. Limited review report of auditors thereon.


The meeting of the Board of Directors commenced at 04.00 P.M (IST) and concluded at 5.00 P.M (IST)

This is for the information and records of the Exchange, please.

Thanking you.

Yours faithfully,
For Sangam Health Care Products Limited


A. Bala Gopal
Managing Director
DIN: (01712903)



Encl: as above

SANGAM HEALTH CARE PRODUCTS LIMITED
205 & 206, AMARCHAND SHARMA COMPLEX, S.P. ROAD, SECUNDERABAD

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED Sep 30, 2019

							(Rs.In Lakhs)
Particulars	Quarter ended			Half Year ended		Year to Date figures for current period ended	
	30/09.2019	30/09/2018	30/06/2019	30/09/2019	30/09/2018	31/03/2019	
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
1	Income from Operations						
(a)	Net Sales/Income from Operations (Net of Excise duty)	666.87	601.05	508.76	1,175.63	1,105.16	2,103.92
(b)	Other Income-	-	0	315.31	315.31	-	4.03
	Total Income	666.87	601.05	824.07	1,490.94	1,105.16	2,107.95
2	Expenditure						
(a)	Cost of Raw material consumed	279.50	301.07	259.06	538.56	589.09	1,041.49
(b)	Purchase of stock-in-trade						
(c)	Change in inventories of Finished Goods Works-in Progress and Stock in Trade	73.70	14.9	(7.73)	65.97	(0.10)	(125.85)
(d)	Employees Benefit Expenses	122.85	125.17	129.36	252.21	255.19	539.76
(e)	Depreciation and Amortization Expenses	34.11	38.07	37.57	71.68	76.14	150.26
(f)	Other Expenditure	162.51	176.43	126.56	289.07	348.88	763.12
	Total expenses	672.67	655.64	544.82	1,217.49	1,269.20	2,368.78
3	Profit from Operations before Other Income, Financial Cost and Exceptional Items (1-2)	(5.80)	(54.59)	279.25	273.45	(164.04)	(260.83)
4	Exceptional Items	-	-	-	-	-	(42.76)
5	Profit / (Loss) from Ordinary Activities before tax (7+8)	(5.80)	(54.59)	279.25	273.45	(164.04)	(218.07)
6	Current tax	-	-	-	-	-	-
	Deferred tax	-	-	-	-	-	(15.27)
7	Net Profit (+)/Loss(-) from Ordinary Activities After Tax (9-10)	-5.80	-54.59	279.25	273.45	-164.04	(202.80)
8	Paid up equity share capital (no of shares) (face value of the share Rs.10/-)	1486.07	1486.07	1486.07	1486.07	1486.07	1,486.07
9	Reserves excluding revaluation reserves	NIL	NIL	NIL	NIL	NIL	NIL
10	Earning Per Share (EPS)	(0.0039)	(0.0367)	0.1879	0.1840	(0.1104)	(0.1365)
	a) Basic and diluted Eps before Extraordinary (not to be annualized)						
	b) Basic and diluted Eps after Extraordinary (not to be annualized)						

Note :

- The above results were reviewed by the Audit Committee and taken on record by the Board of Directors at the meeting held on November,14, 2019
- The Limited Review of the Financials has been carried out by the Statutory Auditors of the Company in terms of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- Previous Accounting period's figures have been grouped/regrouped wherever considered necessary.

Place : Secunderabad
Date: November 14, 2019

For Sangam Health Care Products Limited

A. Balakrishna
Chairman and Managing Director




SANGAM HEALTHCARE PRODUCTS LTD
STATEMENT OF ASSETS & LIABILITIES

PARTICULARS	As at	As at
	30.09.19	31.03.19
	Un audited	Audited
ASSETS		
1.) Non-Current Assets		
a) Property, Plant&Equipments	608.88	1865.00
b) intangible Assets	-	-
c) Capital Work in progress	-	-
d) financial Assets	-	-
investments	-	-
loans	-	-
e) differed Tax assets	-	-
f) other Non current assets	33.59	34.00
Total Non Current Assets (A)	642.47	1899.00
Current Assets		
a) Inventories	190.56	277.00
b) Fiancal Assets		
Trade Receivables	31.85	35.00
Cash & Cash Equivalent	8.65	5.00
short term Loans & advances	174.07	161.00
Other financial Assets	-	-
Total Current Assets (B)	405.13	478.00
Total Assets (A+B)	1047.60	2377.00
EQUITY & LIABILITIES		
1. Equity		
a) Equity Share Capital	1486	1486
b) Other Equity	-3209.91	-3483
Total Equity (A)	-1723.91	-1997.00
2. Non-Current Liabilities		
a) Financial Liabilities Borrowings	48.15	78
b) Deffered Tax Liabilities	133	133
c) Long Term Provisions	66.51	70
Total Non Current Liabilities (B)	247.66	281.00
3. Current Liabilities		
A. Financials		
i) Short term Borrowings	1745.3	2035
ii) Trade Payables	477.18	400
III) other financial liabilities	301.37	258
B) Other Current Liabilities	-	1400
c) Provisions		
d) Current Tax Liabilities		
Total Current Liabilities (C)	2523.85	4093.00
Total Equity & Liabilities (A+B+C)	1047.60	2377.00

For SANGAM HEALTHCARE PRODUCTS LTD


A. Balagopal
Chairman and Managing Director
DIN:01712903



Place: Hyderabad
Date: November 14, 2019

SANGAM HEALTH CARE PRODUCTS LIMITED
CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30th Sep,19

Particulars	30.09.19 (₹)	31.03.2019 (₹)
A. CASH FROM OPERATING ACTIVITIES		
(Loss)/Profit before tax and extraordinary items	27,344,502	(26,084,113)
Adjustment for		
- Depreciation	7,168,377	15,026,427
- Interest & Financial charges	2,471,744	20,996,439
- Interest received	(31,531,010)	(403,647)
Operating Profit before Working Capital Changes	5,453,613	9,535,106
Adjustment for		
- Trade & Other receivables	284,280	(3,385,933)
- Inventories	8,676,971	(18,729,929)
- Trade & others Payable	12,115,178	(68,504,672)
- Short term Loans & Advances	193,938	256,054
- Short Term Borrowings & Provisions	(169,070,193)	187,835,773
Cash flow before Extraordinary items	(142,346,213)	107,006,399
- Interest paid	(2,471,744)	(20,996,439)
- Taxes paid	-	(736,342)
Net Cash flow before extraordinary items	(144,817,957)	85,273,618
-Extraordinary & Prior period items	-	4,276,702
NET CASH FROM OPERATING ACTIVITIES	(144,817,957)	89,550,320
B. CASH FROM INVESTING ACTIVITIES:		
Purchase of Fixed Assets	118,468,990	(2,267,008)
Interest Received	31,531,010	403,647
Long Term Loans & Advances	(1,500,000)	(8,375,898)
NET CASH FROM INVESTING ACTIVITIES	148,500,000	(10,239,259)
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from Long Term Borrowings	(3,000,000)	(80,000,000)
Long Term Provisions	(328,937)	(498,674)
NET CASH FROM FINANCING ACTIVITIES	(3,328,937)	(80,498,674)
NET INCREASE IN CASH & CASH EQUIVALENTS	353,105	(1,187,613)
Opening Cash and cash equivalents	512,575	1,700,188
Closing Cash and Cash equivalents	865,681	512,575

Place: Hyderabad
Date: 14-11-2019

For and on behalf of the Board of Directors

SANGAM HEALTH CARE PRODUCTS LIMITED

BalaGopal Addepalli
BalaGopal Addepalli
Managing Director
DIN No.01712903





CA. M. RAMAKRISHNA

B.Com., F.C.A.

CHARTERED ACCOUNTANT

LIMITED REVIEW REPORT

To.

The Board of Directors.

Sangam Health Care Products limited

We have reviewed the accompanying statement of unaudited financial results of Sangam Health Care Product Limited, ("the company") Secunderabad for the quarter and half year ended 30th Sep, 2019 ("the Statement"). Being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 Dated 5th July 2016.

This Statement is the responsibility of the Company's Management and approved by the board of Directors has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting", prescribed under Section 133 of the companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410. "Review of Interim Financial information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express any audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Accounting Standards(AS) and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M.Ramakrishna,
Chartered Accountants

M.Ramakrishna
Membership No.207169



Place: Hyderabad
Date: 14-11-2019